SBFM
Sunshine Biopharma, Inc.
There isn't enough reported data to score SBFM yet.
SBFM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Unavailable |
SBFM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
SBFM PE Valuation
SBFM has no meaningful PE right now: it lost money over the past year.
SBFM Forward outlook
There aren't enough analyst estimates for SBFM to show an outlook.
SBFM Earnings Per Share
SBFM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.4M | +0.3% |
| Q2 2026 | $9.3M | -1.6% |
| Q1 2026 | $8.1M | -9.1% |
| Q4 2025 | $8.6M | -11% |
| Q3 2025 | $9.4M | +12% |
| Q2 2025 | $9.4M | +1.2% |
| Q1 2025 | $8.9M | +18% |
| Q4 2024 | $9.6M | +25% |
SBFM's revenue is down over the past year, though its latest quarter was up: $9M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -2.1 points |
| Q2 2026 | -17% | +4.4 points |
| Q1 2026 | -17% | -2.7 points |
| Q4 2025 | -21% | +0.4 points |
| Q3 2025 | -12% | +1.6 points |
| Q2 2025 | -22% | -8.2 points |
| Q1 2025 | -15% | +3.3 points |
| Q4 2024 | -21% | -5.8 points |
SBFM's operating margin was −14% last quarter, down 2.1 points from the same quarter a year ago.
SBFM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | -$648.2K |
| Q2 2026 | -$925K | +$508.4K |
| Q1 2026 | -$2.1M | -$355.9K |
| Q4 2025 | -$1.6M | +$1.9M |
| Q2 2025 | -$1.4M | +$3.1M |
| Q1 2025 | -$1.7M | +$1.5M |
| Q4 2024 | -$3.5M | -$1.2M |
| Q1 2024 | -$3.2M | -$1.3M |
SBFM has burned cash in almost every quarter: −$6M over the past year, against −$7M the year before.
SBFM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +178% | +43.7K shares |
| 1 year | +279% | +50.2K shares |
SBFM has 68,266 diluted shares, up 279% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
SBFM Net Leverage
SBFM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SBFM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 19.1 | Oversold |
| Stochastic | 0.9 | Oversold |
SBFM's weekly RSI is 19 (oversold) and its Stochastic is 1 (oversold).
SBFM PE vs Healthcare Sector
SBFM has no meaningful PE right now: it lost money over the past year.
SBFM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.61 | 57% below |
| 20 week MA | $19.3 | 85% below |
| 50 week MA | $123.0 | 98% below |
| 100 week MA | $245.6 | 99% below |
| 200 week MA | $59,597.2 | 100% below |
SBFM is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
SBFM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $200,000.0 | $334,000.0 | +67% |
| 2021 | $334,000.0 | $1,298,000.0 | +289% |
| 2022 | $1,298,000.0 | $264,000.0 | -80% |
| 2023 | $264,000.0 | $108,600.0 | -59% |
| 2024 | $108,600.0 | $612.0 | -99% |
| 2025 | $612.0 | $252.0 | -59% |
| 2026 YTD | $252.0 | $2.84 | -99% |
SBFM has finished four years in a row lower, and it's down 99% so far in 2026.